Abstract: While African Americans are at a signifi cantly higher risk for developing certain cancers, they also have low rates of participation in cancer research, particularly clinical trials. Th is study assessed both African American men's and African American women's (1) knowledge of and participation in cancer-related clinical research and (2) barriers to and motivations for participating in clinical research. Data were collected from a total of 81 participants. Phase I of this research consisted of qualitative focus groups (all 81 participants). Phase II included quantitative pre/ post survey data from an education program (56 participants). Findings from the study revealed that African American men and women had poor knowledge about clinical trials and the informed consent process, limited experience in participating in clinical trials, and they feared and mistrusted cancer research. Participants identifi ed incentives, assurance of safety, knowledge and awareness, and benefi ting others as motivators to participate in clinical trials research.
A frican Americans are more likely to develop and die from cancer than any other racial or ethnic group, in part owing to being diagnosed at later stages. [1] [2] [3] [4] While African Americans are at disproportionately high cancer risk, 1 they also have low rates of participation in cancer research, particularly clinical trials. [5] [6] [7] Prostate cancer incidence and mortality are signifi cantly higher in African American men compared with White men; with incidence approximately 60% higher and mortality approximately 150% higher than in Whites. 1 In addition, the burden of this disease in the state of South Carolina is ≈50% higher than the national average. [8] [9] [10] Despite this, the two largest prostate cancer clinical trials to date included almost no African American men. 11, 12 Th e results of these two studies indicated that screening using the prostate specifi c antigen (PSA) test does not have a substantial eff ect on reducing the prostate cancer mortality rate, does not have a substantial eff ect on reducing the prostate cancer mortality rate but can increase the potential for over diagnosis. Th ese fi ndings, along with other scientifi c evidence, have led to the U.S Preventive Services Task Force's recommendation against routine PSA screening. 13 Th e American Cancer Society (ACS), however, recommends that men make an informed decision with their doctor about whether or not to screen for prostate cancer. 14, 15 Participation in educational programs and clinical trials can help patients make more informed decisions by gaining knowledge about a particular health condition. [16] [17] [18] Despite federal mandates to include women and racial/ ethnic minorities in clinical trials, 19, 20 African Americans generally represent less than 10% of participants in National Cancer Institute (NCI)-sponsored cancer prevention 21 and treatment 22, 23 trials. Barriers to African Americans and other underserved groups' participation in cancer research and clinical trials have been documented widely at the patient, provider, and systems levels. [24] [25] [26] At the patient level, barriers include mistrust of the medical system and of research, 6 ,27-34 strict study eligibility criteria, 27, 35 low-socioeconomic status, 7, 27, 36 lack of health insurance coverage, 22, 37 and limited education about trials. [38] [39] [40] [41] Providers' limited awareness or lack of referral to clinical trials also serve as barriers, [41] [42] [43] [44] and there has been evidence of institutional 44, 45 and structural 46 barriers to African American recruitment and participation. Studies have also shown that African Americans express a need for race/ ethnicity-specifi c disease risk information, 47, 48 and an appreciation of their particular beliefs, values, attitudes, and preferences.
Much of the research on the barriers and facilitators of African Americans' participation in cancer-specifi c trials has focused primarily on African American women. 6, 7, 34, 38 Th erefore, more research involving African American men is warranted. Using CBPR principles, 49, 50 best practice recruitment methods, and culturally and linguistically appropriate communication strategies 51, 52 this pilot research project assessed the knowledge and attitudes of African American men and female spouses, family members, or signifi cant others regarding participation in prostate cancer research.
Methods
Phase 1: Formative focus groups. Twenty-two 90-to 120-minute focus groups (half with men and half with women), were conducted with a total of 81 participants (43 men, mean age 51.0 and 38 women, mean age 50.3) at a local public library in the southeast United States (i.e., South Carolina) (see Table 1 for participant demographics). Men and women were recruited with the assistance of clinical and community partners using various methods such as providing study announcements through media outlets (e.g., radio and newspaper), distributing fl yers at facilities such as barber/ beauty shops and churches, and spreading the message through word-of-mouth in the community. 53 Women were included in this study because prior research has shown that African American women play an active role in fi nding health information for spouses and male relatives and in the health-related decisions of African American men. [54] [55] [56] Th e focus groups aimed to assess participants': 1) current knowledge about and participation in clinical trials, 2) perceptions about clinical trial participation, 3) barriers and incentives for participation in clinical trials, and 4) preferred methods for receiving information about clinical trials. To assess these domains, fi ve questions were included on a 19-item discussion protocol that was co-developed by the research team, National Cancer Institute Community Cancer Centers Program partners, and the community advisory panel. All focus groups were audio-recorded and professionally transcribed.
Qualitative coding and thematic analysis. Transcripts were uploaded and organized into NVivo® 9, 57 a qualitative soft ware program. Prior to the thematic analysis, a codebook was developed by members of the research team through an open-coding process. 58 Th is comprehensive list of codes was used to re-code all transcripts and facilitate the axial coding process conducted by two authors (DBF, OLO). 58 Axial coding is a process used to identify any thematic relationships that exist between codes. 58 Additionally, researchers implemented a constant comparison method by which themes were compared and contrasted across groups (men vs. women). 58 Prior to the focus group discussions, participants also were administered an 18-item survey with questions on demographics (e.g., sex, race, employment, marital status, income), and current, preferred, and feasible sources for health/ cancer information (e.g., regular doctor, radio, email, text message). Th e data from the survey were analyzed using SPSS ® 18.0 59 and nonparametric frequencies/ percentages were calculated. Phase 2: Pilot education intervention. Th e pilot education intervention, developed based on information gained from the community during the phase-1 focus groups, consisted of four one-hour education sessions. Fift y-six of the 81 focus group participants from phase-1 participated in the education sessions which were held in Prior to and following the four education sessions, participants also were asked to complete a 75-question survey to assess potential changes in prostate cancer and clinical trial-related knowledge, perceptions, and behaviors. Th ere were 39 questions that specifi cally assessed clinical trial attitudes and behaviors which were developed based on information from ClinicalTrial .gov's "Understanding Clinical Trials" article, 18 research participation barriers from published literature, and information gained from the phase 1 focus groups. A total of 49 participants (or 87.5%) completed both pre-and post-test surveys, receiving a monetary incentive following the completion of both the pre-and post-test.
Pre/ post-survey analysis. Nonparametric frequencies/ percentages were calculated. Th e Wilcoxon Rank-Sum Test was used for assessing signifi cant pre/ post diff erences for all questions with Likert response options. 60 Th e McNemar-Bowker test, appropriate for non-binary responses, 61, 62 was used to assess the signifi cance of changes between pre-and post-tests for those items with response options of "yes, no, I don't know. " All pre/ post diff erences were considered statistically signifi cant at p < .05.
Results
Phase 1: Focus group themes. Findings from the African American men's and women's focus groups revealed a number of themes that fell into three categories: (1) knowledge, participation, and perception of clinical trials, (2) barriers to participation in clinical trials, and (3) motivation for participating in clinical trials. A ranking of themes and subthemes by gender has been provided in Table 2 to provide a comparative summary of how frequently various themes emerged based on the focus group composition (men versus women).
Knowledge, participation, and perceptions of clinical trials. Overall, male and female participants had limited knowledge about or previous participation in clinical trials, though many reported familiarity with the term "clinical trials. " Despite their lack of specifi c knowledge about clinical trials, both male and female participants had varying perceptions of what types of activities constitute clinical trials.
Men most oft en perceived clinical trials as experimental in nature and commonly referred to the term "guinea pig" when interpreting their perceptions of clinical trials. Women also perceived clinical trials as experimental, but less frequently than male participants. Female focus group participants also most oft en perceived clinical trials to be a type of research and described the research as pertaining to a specifi c disease or health condition. Men less oft en referred to clinical trials as research and their perceptions of research were typically not tied to any specifi c diseases or health conditions. Both women and men perceived clinical trials to be associated with drugs/ prescription medications, but their perceptions diff ered slightly. Women oft en perceived clinical trials as activities leading to the invention of new prescription drugs, general advancements in medicine, and the testing of a medication prior to being released into the marketplace. Men also associated prescription drugs with clinical trials, but instead perceived a clinical trial as a process by which new medications are issued to individual patients by their physicians in an eff ort to identify the most adequate treatment for a specifi c disease. For example, one man said, "I think of like [what] medicine doctors use, just test medicine, like if I was going to switch medications. "
Barriers to participation in clinical trials. When asked specifi cally why they believed African Americans have low participation in clinical trials research, both men and women most oft en discussed fear and mistrust of clinical research. Fear was commonly associated with the uncertainty, lack of knowledge, perceptions about the safety of clinical trial procedures, and the physical discomfort of participating in clinical trials. Mistrust was most oft en attributed to the historic, cultural stigma related to early unethical research studies performed on African American communities (e.g., Tuskegee Syphilis Study). Female and male participants had similar views regarding mistrust being a barrier to African American participation in clinical trials. For example, one female participant stated, "I just think the younger you are, in the Black community, the more likely you probably are going to participate. But older people that grew up during that time we heard more about the Tuskegee experiments and stuff and what happened to those men and their families. . . . I think it's just mistrust and fear. " Th e time commitment/ schedule fi t also was expressed by both male and female participants equally as a key barrier to participation in clinical trial research among African Americans. Comments related to participants' individual experiences and their thoughts on why they feel that people in their community also do not participate in research. Th ese time constraints were commonly linked to family obligations such as serving as a caretaker for a family member or work commitments.
Motivators for participation in clinical trials. When asked what incentives would motivate participants and people in their community to participate in clinical trials research, the most commonly reported incentives included money, assurance of safety while participating in the clinical trial, education regarding clinical trial procedures, the potential for the research to benefi t someone in their family or community, encouragement from peers, and free healthcare. Male and female participants most oft en mentioned money as the most promising incentive for motivating community members to participate in clinical research.
Male participants asserted that safety and full disclosure of potential adverse eff ects would play an exceedingly important role in whether they or others in their communities would participate in a clinical trial. When asked what would motivate him and other African American men to participate in a clinical trial, one male participant stated, "I think most of us would like to hear something like 'no risk. ' " Men also reported that having full disclosure of any procedures and potential side eff ects of prescribed treatments may motivate them to participate in a clinical trial. Women did not mention safety as a motivator for clinical trial participation.
Aft er monetary incentives, women felt that helping someone in their family or community would be the strongest motivator for encouraging African Americans to participate in clinical research, particularly if it could "save the life" of someone they knew. Male participants less oft en mentioned helping someone as a motivator for promoting clinical trial participation. Male and female participants both reported that making the community more aware of clinical trials, and their specifi c protocols, would be a potential motivator for their participation.
Female participants reported peer encouragement as a stronger motivator for persuading them or others to participate in clinical trials than male participants. Th ese women and men reported that encouragement could occur through the personal experience of an acquaintance (e.g., friend had a positive clinical trial experience) or through social support provided by family or friends. For example, a female participant commented on the persuasiveness of peer support to convince a person to participate in a clinical trial. She stated, "You know, you could say [to a peer], 'Well, you know . . . I'm going to a prostate study, ' . . . You know, they might listen. " Some male and female participants reported not having access to healthcare and therefore indicated that receiving free medications and/or other medical services could serve as an incentive for motivating African Americans to participate in clinical trials. Th ese resources were reported less oft en in female and male groups compared with the other incentives. See Table 2 for a ranked list of themes and subthemes.
Phase 2: Education program survey results. Th e reported results are based on those items that exhibited the most meaningful changes between pre-and post-tests (see Table 3 ). Few met conventional criteria for signifi cance (and should not be 63 Participation in clinical trials. Th e majority of participants reported never participating in a clinical trial and never being asked by their doctor to participate in clinical research. However, most male and female participants said that they would be open to being involved in a cancer clinical trial in the future. Following the four-week education intervention there was a slight, but non-signifi cant, increase in participants' openness to participate in a clinical trial in the future.
Men and women expressed similar likelihoods of participating in clinical trials at both pre-and post-test. Men, however, reported being open to participating in clinical trials in the future more oft en than women prior to the educational intervention. Following the intervention, both men and women reported being about equally open to participating in clinical trials in the future. Additionally, male and female participants either strongly agreed or agreed that they would be willing to participate in clinical trials if they had a good understanding about why the trial is being done. Th ese numbers were similar at post-test. Furthermore, there was a decrease from the pre-to the post-test in the number of men who believed that medical experiments can be done without them knowing about it.
Barriers to participation in clinical trials. Th e largest barrier reported by all respondents for not participating in a clinical trial in the past was time commitment/ schedule fi t followed by transportation, mistrust, poor compensation, informed consent being too complicated, and pressure from researchers. When stratifi ed by sex, male respondents ranked transportation as the largest barrier to clinical trial participation at pre-test followed by time commitment/ schedule fi t, mistrust, poor compensation, informed consent being too complicated, and pressure from researchers. At post-test most men indicated time commitment/ schedule fi t as the top barrier. Other barriers included: mistrust, informed consent too complicated, transportation, compensation, and pressure from researchers.
At pre-test, the majority of women respondents reported transportation as a barrier to clinical trial participation. Mistrust, poor compensation, time commitment/ schedule fi t, and a too-complicated informed consent process were also reported as barriers. Pressure from researchers was not reported as a barrier at either pre-test or post-test. At post-test, time commitment/ schedule fi t was reported as the most common barrier to clinical trial participation among women. Other-barriers were less oft en reported. Table 3 presents a summary of barriers to participation in clinical trials.
Discussion
Our study assessed African American men and women's 1) knowledge of and participation in clinical research and 2) barriers to and motivations for participation in clinical research. Th is study is one of few mixed methods studies on clinical trials knowledge and perceptions to be conducted with African American men and also one of the fi rst to be conducted with both African American men and women. 64 Determining to what extent African American men and women understand and participate in clinical research and the barriers and motivators to their participation researchers can determine the most optimal strategies for engaging high-risk African American communities in clinical research. It is essential that researchers, clinicians, and other stakeholders work together to eliminate barriers that can increase African Americans' participation in clinical trials research if we are to answer important questions about racial diff erences in what drives their high burden of cancer.
1 African Americans' involvement in clinical research could lead to advancements in medicine and public health practice that result in reducing health disparities. For example, a recent statement by the U.S. Preventive Services Task Force recommends that healthy men should not receive PSA screenings. 13 However, the research evidence on which these recommendations were based includes virtually no African American men, and none from high-risk groups in the American South (who have the highest prostate cancer rates in the world and who represent 55% of all Americans of African descent). [8] [9] [10] [11] [12] 65, 66 Th e fi ndings from our study reveal many common themes among African American men and women regarding clinical research; however, emphasis on particular themes varied. Overall, both male and female participants had poor knowledge about clinical trials and the informed consent process and reported only limited participation in clinical trials. When asked about the term "clinical trials, " few participants had a clear idea of what constitutes a clinical trial. Some participants, instead, provided researchers with their personal perceptions of clinical research or what information they had learned from sources such as the media or other community members. Many times these perceptions were either incorrect or negative (e.g., African American men commonly confused the "trial and error" process of fi nding the correct medication dosage with their enrollment in a clinical trial), but likely stemmed from limited resources to inform the community about clinical trials and from the "guinea pig" stigma that permeates through the African American community. Our qualitative data demonstrates that fear and mistrust were considered the most commonly reported themes followed by time commitment/ schedule fi t. Th ese themes emerged similarly in male and female focus groups. Fear was typically associated with participants' lack of knowledge about clinical trials and some of the misperceptions about clinical trials. Mistrust has stemmed from the history of African Americans who have participated in research, particularly the Tuskegee Syphilis study. 67 Mistrust and fear also have been shown as limiting factors in other studies which have examined barriers to African American participants in clinical research. 32, 68, 69 For example, Williams and colleagues found that mistrust was a "fundamental reason" why African Americans did not participate in Alzheimer's Disease biomarker research. 32 Th rough our qualitative analysis, we also found that mistrust was a commonly reported barrier. However, mistrust was reported much less oft en in our quantitative fi ndings at pre-test (8%) and post-test (15%) than the most commonly reported barrier (i.e., time commitment/ schedule fi t), which was reported by 32% of respondents at pre-test and 55% at post-test. Despite the diff erences in our qualitative and quantitative fi ndings regarding the most commonly reported barriers, mistrust, fear, and time are the three prevailing barriers among our African American study participants.
Male and female participants reported a number of incentives that could help motivate African Americans to participate in clinical trials. Money was reported most oft en as a motivator for encouraging African Americans to participate. In a recent systematic review of 397 papers (37 studies), which discussed recruitment strategies, money was shown to signifi cantly improve recruitment of patients into clinical trials. 70 Other studies also have shown money to be a motivating factor. 71, 72 However, no prior studies found that money alone increased the recruitment of African Americans. In addition, other research shows that using money to recruit subjects is unethical because of undue coercion of an individual to participate or remain in a study because of the incentive as opposed to the potential risks or benefi ts. [72] [73] [74] Th e second most reported motivator by men was the assurance of safety, while women reported wanting general awareness and education. Th e third most reported motivator by men was receiving education. Th e third most reported motivator by women (4th most commonly reported among men) was helping someone such as a friend or family member. Th is fi nding is consistent with previous studies showing that individuals participated in clinical research because they knew it would benefi t a family member or society as a whole. 75, 76 Peer encouragement also was cited as a strong motivator by men and women, particularly when opinion leaders such as pastors and friends provided assurance regarding the safety and importance of clinical trials. Prior research has indicated that pastors and peers do play an infl uential role in African Americans' participation in research and the adoption of healthier behavior. 77, 78 Finally, free healthcare was least oft en mentioned by men and women as a motivator for participation in clinical trials; however, lack of health insurance was demonstrated as an issue among this group. Prior research has shown that free healthcare may motivate African Americans' participation in research, 79 particularly because there is a disparity in health insurance coverage among African Americans as compared to their White counterparts. 75, 79 Colon-Otero and colleagues specifi cally noted that national healthcare reform that ensures universal healthcare coverage will diminish barriers to cancer clinical trial enrollment that uninsured and underinsured patients encounter. 79 Th e legacy of slavery, segregation, and unequal civil rights that spanned into the late 20th century give African Americans apprehension about trusting a predominantly White establishment. 6 Furthermore, socioeconomic factors related to education, employment, and health insurance status also limit enrollment of African Americans into medical research. 6 Our study demonstrates that many of the aforementioned barriers do, in fact, hinder African Americans from participating in cancer-related clinical trial research (e.g., mistrust, fear, time), but these barriers can be ameliorated or overcome through a combination of strategies which include culturally appropriate education, informing the community about eligible clinical research, clear disclosure about study procedures and benefi ts of research, schedule accommodation, and monetary incentives.
Based on our fi ndings ( Table 2 ) that men and women demonstrated similar overall clinical trial knowledge and types of barriers to participation, educational content and eff orts to eliminate barriers to participation/ recruitment (e.g., fl exible hours) should be similar. However, educational content for men, in particular, should focus more on ameliorating their perception of clinical trials as guinea pig experiments, whereas education eff orts for women should focus on improving their understanding of clini-cal trials beyond their knowledge of the term being related to research. Furthermore, institutions should keep the community informed about the successes of research that materialize through various studies. Lastly, clinical researchers should encourage those African Americans who do participate in clinical trials to share their experience with others and encourage them to become involved in future research. By striving to implement some of the aforementioned strategies using a community-engaged approach, we believe that cancer researchers can increase the participation of African Americans in their clinical studies.
Limitations. Th is mixed-methods study has limitations. Th e sample consisted of a small number of African American men and women from one mid-sized city in a southern state. Th erefore, the results from this study may not be generalizable to African American men and women in the state or other regions of the U.S. In addition, the results cannot be generalized to other racial and ethnic groups. Despite these limitations, this study provided valuable information that can contribute to the future development of culturally appropriate strategies to recruit African American men and women for participation in cancer-related clinical trials research. Th e mixed methods approach greatly strengthened the study design because it allowed us to use data from our formative qualitative research to customize an intervention that was appropriate for our participants and provided us with expansive information about barriers to clinical trial participation that we would otherwise have not received through the utilization of a strictly quantitative survey approach. In addition, including both men and women in our study provided us with a holistic, family-centered perspective on African Americans and clinical trials and provided a shared learning environment where men and women could participate in cancer-focused dialogue that we encouraged to extend beyond the education program. 
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